Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $1.4 billion.

  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity rose 21.54% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 48.49%. This contributed to the annual value of $1.4 billion for FY2025, which is 21.54% up from last year.
  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.4 billion in Q3 2025, which was up 0.34% from $1.4 billion recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.6 billion during Q1 2025, with a 5-year trough of $626.3 million in Q4 2023.
  • In the last 3 years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $955.1 million in 2024 and averaged $1.0 billion.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity fell by 29.75% in 2023 and then surged by 64.74% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $638.5 million in 2021, then surged by 39.61% to $891.5 million in 2022, then dropped by 29.75% to $626.3 million in 2023, then spiked by 61.86% to $1.0 billion in 2024, then grew by 21.54% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.4 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.6 billion in Q1 2025.